Retrospective Study of Cases of Small Cell Lung Cancer (SCLC) That Appeared During Treatment of Another Lung Carcinoma With or ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2016-2017

ABSTRACT

The discovery of oncogenic mutations and the use of targeted therapies have transformed the management of certain tumors. Thus 12 to 15% of bronchial adenocarcinomas (AD) carry mutations of EGFR and receive from the first line inhibitors of this kinase (ITK). Despite spectacular results, relapse and resistance are quasi-general phenomena. In most known cases, EGFR-TKI resistance mechanisms involve secondary mutations of EGFR or the activation of alternative oncogenic pathways. However, in 5 to 15% of patients, resistance is manifested by the emergence of a small cell carcinoma (CPC), a cancer of neuroendocrine origin very different from AD by its cellular, molecular and epidemiological characteristics. This phenotypic transformation is an almost unique phenomenon in oncology and its molecular bases are not understood. To study this phenomenon, a Franco-Italian network was established that documented and collected cases of this rare tumor. This series is the subject of detailed anatomopathological, clinical and therapeutic documentation. This project aims to investigate the exome of one or more matched lesion regions to evaluate the evolutionary processes leading from the initial AD to the relapsing CPC. These results will guide future research on predictive markers of relapse and their targeted treatment. Detailed Description An international multicentric retrospective collection of cases was performed between 2005 and 2017. A global e-mailing to a network of thoracic oncology centers in France and Italy called for the selection of retrospective cases. Consecutive non small cell lung cancer (NSCLC) patients with stage III or IV EGFR NSCLC with or without initial EGFR mutation with a secondary transformation to small cell lung cancer (SCLC) in participating centers in France and Italy were included. Patients with a previous history of SCLC or neuroendocrine tumor of the lung were excluded as well as patients with combined Small cell/ Non-small cell lung cancer on the initial pathology sample. Study ethics approval was obtained on December 8th of 2015 (CECIC Rhône-Alpes-Auvergne, Clermont-Ferrand, IRB 5891). Anonymized data were collected at each center then centrally analyzed at the Albert Bonniot Institute, Inserm U 823, Grenoble Alpes University, in Grenoble, France. The primary objective of this study was to analyze survival data after transformation to SCLC. The secondary objectives were to define: the epidemiological characteristics at the time of diagnosis of NSCLC, the histomolecular characteristics at the time of diagnosis of NSCLC and at the time of diagnosis of SCLC; the clinical characteristics at the time of diagnosis of NSCLC and SCLC and the treatment characteristics before and after transformation from NSCLC to SCLC. All identified cases will be analyzed. This concerns about sixty two patients because the transformation into small cell lung cancer is a rare mechanism of resistance, it is for this reason that all the cases will be included in order to obtain the most exhaustive data possible. Continuous variables were described as median (25%-75% interquartile range [IQR]) and categorical variables as number (%). Associations between categorical variables were compared using the chi-2 test or Fisher's exact test and those between continuous variables using the Wilcoxon test. Patients were followed until November of 2017. Overall survival (OS) is the time from the initial diagnosis of lung cancer to death and survival after SCLC transformation is from the rebiopsy to death. Kaplan-Meier plots of survival curves were compared between groups using the log-rank test. All tests were two-sided, and P values <0.05 were considered statistically significant. All statistical analyses were performed using SAS 9.3 (SAS Institute, Cary, NC, USA). More... »

URL

https://clinicaltrials.gov/show/NCT03419286

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The discovery of oncogenic mutations and the use of targeted therapies have transformed the management of certain tumors. Thus 12 to 15% of bronchial adenocarcinomas (AD) carry mutations of EGFR and receive from the first line inhibitors of this kinase (ITK). Despite spectacular results, relapse and resistance are quasi-general phenomena. In most known cases, EGFR-TKI resistance mechanisms involve secondary mutations of EGFR or the activation of alternative oncogenic pathways. However, in 5 to 15% of patients, resistance is manifested by the emergence of a small cell carcinoma (CPC), a cancer of neuroendocrine origin very different from AD by its cellular, molecular and epidemiological characteristics. This phenotypic transformation is an almost unique phenomenon in oncology and its molecular bases are not understood. To study this phenomenon, a Franco-Italian network was established that documented and collected cases of this rare tumor. This series is the subject of detailed anatomopathological, clinical and therapeutic documentation. This project aims to investigate the exome of one or more matched lesion regions to evaluate the evolutionary processes leading from the initial AD to the relapsing CPC. These results will guide future research on predictive markers of relapse and their targeted treatment.\n\nDetailed Description\nAn international multicentric retrospective collection of cases was performed between 2005 and 2017. A global e-mailing to a network of thoracic oncology centers in France and Italy called for the selection of retrospective cases. Consecutive non small cell lung cancer (NSCLC) patients with stage III or IV EGFR NSCLC with or without initial EGFR mutation with a secondary transformation to small cell lung cancer (SCLC) in participating centers in France and Italy were included. Patients with a previous history of SCLC or neuroendocrine tumor of the lung were excluded as well as patients with combined Small cell/ Non-small cell lung cancer on the initial pathology sample. Study ethics approval was obtained on December 8th of 2015 (CECIC Rh\u00f4ne-Alpes-Auvergne, Clermont-Ferrand, IRB 5891). Anonymized data were collected at each center then centrally analyzed at the Albert Bonniot Institute, Inserm U 823, Grenoble Alpes University, in Grenoble, France. The primary objective of this study was to analyze survival data after transformation to SCLC. The secondary objectives were to define: the epidemiological characteristics at the time of diagnosis of NSCLC, the histomolecular characteristics at the time of diagnosis of NSCLC and at the time of diagnosis of SCLC; the clinical characteristics at the time of diagnosis of NSCLC and SCLC and the treatment characteristics before and after transformation from NSCLC to SCLC. All identified cases will be analyzed. This concerns about sixty two patients because the transformation into small cell lung cancer is a rare mechanism of resistance, it is for this reason that all the cases will be included in order to obtain the most exhaustive data possible. Continuous variables were described as median (25%-75% interquartile range [IQR]) and categorical variables as number (%). Associations between categorical variables were compared using the chi-2 test or Fisher's exact test and those between continuous variables using the Wilcoxon test. Patients were followed until November of 2017. Overall survival (OS) is the time from the initial diagnosis of lung cancer to death and survival after SCLC transformation is from the rebiopsy to death. Kaplan-Meier plots of survival curves were compared between groups using the log-rank test. All tests were two-sided, and P values <0.05 were considered statistically significant. All statistical analyses were performed using SAS 9.3 (SAS Institute, Cary, NC, USA).", 
    "endDate": "2017-11-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT03419286", 
    "keywords": [
      "retrospective study", 
      "Small Cell Lung Carcinoma", 
      "lung carcinoma", 
      "oncogenic activation", 
      "discovery", 
      "oncogenic mutation", 
      "targeted therapy", 
      "management", 
      "certain tumor", 
      "adenocarcinoma", 
      "AD", 
      "mutation", 
      "EGFR", 
      "first line", 
      "inhibitor", 
      "Recurrence", 
      "resistance", 
      "general phenomenon", 
      "known case", 
      "resistance mechanism", 
      "secondary mutation", 
      "oncogenic pathway", 
      "patient", 
      "emergence", 
      "carcinoma", 
      "Neoplasm", 
      "origin", 
      "characteristic", 
      "phenotypic transformation", 
      "unique phenomenon", 
      "oncology", 
      "molecular base", 
      "phenomenon", 
      "network", 
      "rare tumor", 
      "documentation", 
      "exome", 
      "lesion", 
      "evolutionary process", 
      "relapsing", 
      "guide future research", 
      "predictive marker", 
      "targeted treatment", 
      "International", 
      "France and Italy", 
      "selection", 
      "non small cell lung cancer", 
      "stage III", 
      "EGFR mutation", 
      "transformation", 
      "previous history", 
      "neuroendocrine tumor", 
      "lung", 
      "pathology", 
      "approval", 
      "December", 
      "anonymized data", 
      "Institute", 
      "US", 
      "Grenoble", 
      "France", 
      "primary objective", 
      "survival data", 
      "secondary objective", 
      "diagnosis", 
      "clinical characteristic", 
      "treatment characteristic", 
      "Rare", 
      "continuous variable", 
      "categorical variable", 
      "association", 
      "Fisher's", 
      "November", 
      "survival", 
      "OS", 
      "initial diagnosis", 
      "Lung Neoplasm", 
      "death", 
      "small-cell lung cancer", 
      "Kaplan-Meier", 
      "survival curve", 
      "rank", 
      "p-values", 
      "statistical analysis", 
      "SA", 
      "NC", 
      "USA"
    ], 
    "name": "Retrospective Study of Cases of Small Cell Lung Cancer (SCLC) That Appeared During Treatment of Another Lung Carcinoma With or Without Oncogenic Activation (TransCPC)", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT03419286"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00026.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.410529.b", 
        "type": "Organization"
      }
    ], 
    "startDate": "2016-02-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/1756-9966-29-75", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007907779", 
          "https://doi.org/10.1186/1756-9966-29-75"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)71180-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009467492"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-2246", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017730793"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/jclinpath-2014-202447", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018642450"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-07-4622", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020739606"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/scitranslmed.3002003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026701764"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ncomms7377", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041168235", 
          "https://doi.org/10.1038/ncomms7377"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.1254721", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043398287"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/srep14447", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049954191", 
          "https://doi.org/10.1038/srep14447"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.71.9096", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085402598"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT03419286"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT03419286'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT03419286'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT03419286'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT03419286'


 

This table displays all metadata directly associated to this object as RDF triples.

139 TRIPLES      16 PREDICATES      112 URIs      96 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT03419286 schema:about anzsrc-for:3142
2 schema:description The discovery of oncogenic mutations and the use of targeted therapies have transformed the management of certain tumors. Thus 12 to 15% of bronchial adenocarcinomas (AD) carry mutations of EGFR and receive from the first line inhibitors of this kinase (ITK). Despite spectacular results, relapse and resistance are quasi-general phenomena. In most known cases, EGFR-TKI resistance mechanisms involve secondary mutations of EGFR or the activation of alternative oncogenic pathways. However, in 5 to 15% of patients, resistance is manifested by the emergence of a small cell carcinoma (CPC), a cancer of neuroendocrine origin very different from AD by its cellular, molecular and epidemiological characteristics. This phenotypic transformation is an almost unique phenomenon in oncology and its molecular bases are not understood. To study this phenomenon, a Franco-Italian network was established that documented and collected cases of this rare tumor. This series is the subject of detailed anatomopathological, clinical and therapeutic documentation. This project aims to investigate the exome of one or more matched lesion regions to evaluate the evolutionary processes leading from the initial AD to the relapsing CPC. These results will guide future research on predictive markers of relapse and their targeted treatment. Detailed Description An international multicentric retrospective collection of cases was performed between 2005 and 2017. A global e-mailing to a network of thoracic oncology centers in France and Italy called for the selection of retrospective cases. Consecutive non small cell lung cancer (NSCLC) patients with stage III or IV EGFR NSCLC with or without initial EGFR mutation with a secondary transformation to small cell lung cancer (SCLC) in participating centers in France and Italy were included. Patients with a previous history of SCLC or neuroendocrine tumor of the lung were excluded as well as patients with combined Small cell/ Non-small cell lung cancer on the initial pathology sample. Study ethics approval was obtained on December 8th of 2015 (CECIC Rhône-Alpes-Auvergne, Clermont-Ferrand, IRB 5891). Anonymized data were collected at each center then centrally analyzed at the Albert Bonniot Institute, Inserm U 823, Grenoble Alpes University, in Grenoble, France. The primary objective of this study was to analyze survival data after transformation to SCLC. The secondary objectives were to define: the epidemiological characteristics at the time of diagnosis of NSCLC, the histomolecular characteristics at the time of diagnosis of NSCLC and at the time of diagnosis of SCLC; the clinical characteristics at the time of diagnosis of NSCLC and SCLC and the treatment characteristics before and after transformation from NSCLC to SCLC. All identified cases will be analyzed. This concerns about sixty two patients because the transformation into small cell lung cancer is a rare mechanism of resistance, it is for this reason that all the cases will be included in order to obtain the most exhaustive data possible. Continuous variables were described as median (25%-75% interquartile range [IQR]) and categorical variables as number (%). Associations between categorical variables were compared using the chi-2 test or Fisher's exact test and those between continuous variables using the Wilcoxon test. Patients were followed until November of 2017. Overall survival (OS) is the time from the initial diagnosis of lung cancer to death and survival after SCLC transformation is from the rebiopsy to death. Kaplan-Meier plots of survival curves were compared between groups using the log-rank test. All tests were two-sided, and P values <0.05 were considered statistically significant. All statistical analyses were performed using SAS 9.3 (SAS Institute, Cary, NC, USA).
3 schema:endDate 2017-11-01T00:00:00Z
4 schema:keywords AD
5 December
6 EGFR
7 EGFR mutation
8 Fisher's
9 France
10 France and Italy
11 Grenoble
12 Institute
13 International
14 Kaplan-Meier
15 Lung Neoplasm
16 NC
17 Neoplasm
18 November
19 OS
20 Rare
21 Recurrence
22 SA
23 Small Cell Lung Carcinoma
24 US
25 USA
26 adenocarcinoma
27 anonymized data
28 approval
29 association
30 carcinoma
31 categorical variable
32 certain tumor
33 characteristic
34 clinical characteristic
35 continuous variable
36 death
37 diagnosis
38 discovery
39 documentation
40 emergence
41 evolutionary process
42 exome
43 first line
44 general phenomenon
45 guide future research
46 inhibitor
47 initial diagnosis
48 known case
49 lesion
50 lung
51 lung carcinoma
52 management
53 molecular base
54 mutation
55 network
56 neuroendocrine tumor
57 non small cell lung cancer
58 oncogenic activation
59 oncogenic mutation
60 oncogenic pathway
61 oncology
62 origin
63 p-values
64 pathology
65 patient
66 phenomenon
67 phenotypic transformation
68 predictive marker
69 previous history
70 primary objective
71 rank
72 rare tumor
73 relapsing
74 resistance
75 resistance mechanism
76 retrospective study
77 secondary mutation
78 secondary objective
79 selection
80 small-cell lung cancer
81 stage III
82 statistical analysis
83 survival
84 survival curve
85 survival data
86 targeted therapy
87 targeted treatment
88 transformation
89 treatment characteristic
90 unique phenomenon
91 schema:name Retrospective Study of Cases of Small Cell Lung Cancer (SCLC) That Appeared During Treatment of Another Lung Carcinoma With or Without Oncogenic Activation (TransCPC)
92 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT03419286
93 schema:sdDatePublished 2019-03-07T15:27
94 schema:sdLicense https://scigraph.springernature.com/explorer/license/
95 schema:sdPublisher N2357fc61eb1542158a24b318b383b344
96 schema:sponsor https://www.grid.ac/institutes/grid.410529.b
97 schema:startDate 2016-02-01T00:00:00Z
98 schema:subjectOf sg:pub.10.1038/ncomms7377
99 sg:pub.10.1038/srep14447
100 sg:pub.10.1186/1756-9966-29-75
101 https://doi.org/10.1016/s1470-2045(14)71180-5
102 https://doi.org/10.1126/science.1254721
103 https://doi.org/10.1126/scitranslmed.3002003
104 https://doi.org/10.1136/jclinpath-2014-202447
105 https://doi.org/10.1158/1078-0432.ccr-07-4622
106 https://doi.org/10.1158/1078-0432.ccr-12-2246
107 https://doi.org/10.1200/jco.2016.71.9096
108 schema:url https://clinicaltrials.gov/show/NCT03419286
109 sgo:license sg:explorer/license/
110 sgo:sdDataset clinical_trials
111 rdf:type schema:MedicalStudy
112 N2357fc61eb1542158a24b318b383b344 schema:name Springer Nature - SN SciGraph project
113 rdf:type schema:Organization
114 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
115 rdf:type schema:DefinedTerm
116 sg:pub.10.1038/ncomms7377 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041168235
117 https://doi.org/10.1038/ncomms7377
118 rdf:type schema:CreativeWork
119 sg:pub.10.1038/srep14447 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049954191
120 https://doi.org/10.1038/srep14447
121 rdf:type schema:CreativeWork
122 sg:pub.10.1186/1756-9966-29-75 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007907779
123 https://doi.org/10.1186/1756-9966-29-75
124 rdf:type schema:CreativeWork
125 https://doi.org/10.1016/s1470-2045(14)71180-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009467492
126 rdf:type schema:CreativeWork
127 https://doi.org/10.1126/science.1254721 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043398287
128 rdf:type schema:CreativeWork
129 https://doi.org/10.1126/scitranslmed.3002003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026701764
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1136/jclinpath-2014-202447 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018642450
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1158/1078-0432.ccr-07-4622 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020739606
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1158/1078-0432.ccr-12-2246 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017730793
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1200/jco.2016.71.9096 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085402598
138 rdf:type schema:CreativeWork
139 https://www.grid.ac/institutes/grid.410529.b schema:Organization
 




Preview window. Press ESC to close (or click here)


...